Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7

World Journal of Urology

Volumn 34, Issue 5, 2016, Pages 633-639

  Zengerling, Friedemann ^a   Azoitei, Anca ^a   Herweg, Alexander ^a   Jentzmik, Florian ^a   Cronauer, Marcus V ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

AR V7; Castration resistant prostate cancer; IGF 1 receptor; Q640X

Indexed keywords

ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; SOMATOMEDIN C;

ANTAGONISTS AND INHIBITORS; HUMAN; MALE; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84941343437     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1674-5     Document Type: Article

References (31)

1. Knudsen KE, Penning TM (2010) Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21:315–324. doi:10.1016/j.tem.2010.01.002
2. Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM (2014) Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. EndocrRelat Cancer 21:T87–t103. doi:10.1530/erc-13-0470
3. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913–5925. doi:10.1158/1078-0432.ccr-11-0728
4. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM (2013) Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 73:483–489. doi:10.1158/0008-5472.can-12-3630
5. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474–5478
6. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M (2001) In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61:6276–6280
7. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A (2005) Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65:1849–1857. doi:10.1158/0008-5472.can-04-1837
8. Turney BW, Turner GD, Brewster SF, Macaulay VM (2011) Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int 107:1488–1499. doi:10.1111/j.1464-410X.2010.09556.x
9. Liu X, Choi RY, Jawad SM, Arnold JT (2011) Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells. Prostate 71:766–777. doi:10.1002/pros.21293
10. Lapouge G, Marcias G, Erdmann E, Kessler P, Cruchant M, Serra S, Bergerat JP, Ceraline J (2008) Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 617:529–534. doi:10.1007/978-0-387-69080-3_53
11. Zengerling F, Streicher W, Schrader AJ, Schrader M, Nitzsche B, Cronauer MV, Hopfner M (2012) Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. Int J Mol Sci 13:11530–11542. doi:10.3390/ijms130911530
12. Ceraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP (2004) Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 108:152–157. doi:10.1002/ijc.11404
13. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469–5477. doi:10.1158/0008-5472.can-08-0594
14. Streicher W, Luedeke M, Azoitei A, Zengerling F, Herweg A, Genze F, Schrader MG, Schrader AJ, Cronauer MV (2014) Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARDeltaLBD-signalling in human prostate cancer cells. PLoS ONE 9(6):e98566. doi:10.1371/journal.pone.0098566
15. Streicher W, Zengerling F, Laschak M, Weidemann W, Hopfner M, Schrader AJ, Jentzmik F, Schrader M, Cronauer MV (2012) AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J Urol 30:333–339. doi:10.1007/s00345-012-0842-0
16. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715–2730. doi:10.1172/jci41824
17. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R (1993) Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102–1106
18. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S (2005) Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J 19:2042–2044. doi:10.1096/fj.05-3740fje
19. Gioeli D, Paschal BM (2012) Post-translational modification of the androgen receptor. Mol Cell Endocrinol 352:70–78. doi:10.1016/j.mce.2011.07.004
20. Chen S, Gulla S, Cai C, Balk SP (2012) Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem 287:8571–8583. doi:10.1074/jbc.M111.325290
21. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR (2006) Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99:392–401. doi:10.1002/jcb.20929
22. Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G (2015) Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep 5:7654. doi:10.1038/srep07654
23. Iwamura M, Sluss PM, Casamento JB, Cockett AT (1993) Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22:243–252
24. Philippou A, Armakolas A, Koutsilieris M (2013) Evidence for the possible biological significance of the igf-1 gene alternative splicing in prostate cancer. Front Endocrinol (Lausanne) 4:31. doi:10.3389/fendo.2013.00031
25. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky AD, Qiu Y (2014) Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem 289:1529–1539. doi:10.1074/jbc.M113.492140
26. Kesler CT, Gioeli D, Conaway MR, Weber MJ, Paschal BM (2007) Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol Endocrinol 21:2071–2084. doi:10.1210/me.2007-0240
27. Koryakina Y, Ta HQ, Gioeli D (2014) Androgen receptor phosphorylation: biological context and functional consequences. Endocr Relat Cancer 21:T131–T145. doi:10.1530/erc-13-0472
28. Loughran G, Huigsloot M, Kiely PA, Smith LM, Floyd S, Ayllon V, O’Connor R (2005) Gene expression profiles in cells transformed by overexpression of the IGF-I receptor. Oncogene 24:6185–6193. doi:10.1038/sj.onc.1208772
29. Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z (2008) Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci USA 105:7570–7575. doi:10.1073/pnas.0712306105
30. Kato H, Sekine Y, Furuya Y, Miyazawa Y, Koike H, Suzuki K (2015) Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem Biophys Res Commun. doi:10.1016/j.bbrc.2015.03.178
31. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D, Pollak M, Lui L, Endt K, Schiess R, Ruschoff JH, Cathomas R, Gillessen S (2014) Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). Eur Urol 66:468–474. doi:10.1016/j.eururo.2013.12.057